Platelet microRNA for predicting acute myocardial infarction

Area of Science:

• Cardiovascular Medicine
• Molecular Biology
• Biomarker Discovery

Background:

• Acute myocardial infarction (AMI) diagnosis is critical for patient outcomes.
• Platelet activation plays a key role in AMI pathogenesis.
• The diagnostic value of platelet microRNAs (pmiRNAs) in AMI remains unclear.

Purpose of the Study:

• To investigate the expression levels of specific pmiRNAs in ST-segment elevation myocardial infarction (STEMI) patients.
• To explore the correlation between pmiRNA levels and platelet activity indices.
• To evaluate the potential of pmiRNAs as diagnostic biomarkers for STEMI.

Main Methods:

• Prospective assessment of platelet miR-1, miR-21, miR-126, miR-150, and miR-223 expression in STEMI patients and healthy controls.
• Measurement of platelet reactive units (PRU) and vasodilator-stimulated phosphoprotein (VASP) as indices of platelet activity.
• Correlation analysis between pmiRNA levels, cardiac troponin I, PRU, and VASP.

Main Results:

• pmiR-21 and pmiR-126 expression were decreased, while pmiR-150 and pmiR-223 were increased in STEMI patients compared to controls.
• Only pmiR-126 showed a significant correlation with plasma cardiac troponin I.
• No significant correlations were found between pmiRNAs and PRU or VASP at admission or 48 hours post-stenting.

Conclusions:

• pmiR-126 may serve as a potential novel biomarker for STEMI.
• pmiR-1, pmiR-21, pmiR-150, and pmiR-223 have limited diagnostic utility for STEMI.
• The limited correlation between pmiRNA expression and platelet activity indices suggests restricted diagnostic value.